Evidence map›Paper›PMID 37961390›Full record

ArticlebioRxiv : the preprint server for biology2023

Jian Wang, Bo Chao, Jake Piesner, Felice Kelly, Stefanie Kaech Petrie, Xiangshu Xiao, Bingbing X Li

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Updated by
    2024
5 · Who and what money

Authors and funding

7 authors.

Jian Wang
Bo Chao
Jake Piesner
Felice Kelly
Stefanie Kaech Petrie
Xiangshu Xiao

Funding

Small molecules targeting RuvBL complex for triple negative breast cancerR01CA278058 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bingbing Li, Xiangshu Xiao · 2023 to 2026
$2.4M
Targeting EWS-ATF1 Fusion in Clear Cell Sarcoma of Soft TissueR01CA245964 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bingbing Li · 2022 to 2026
$2.2M
Chemical Modulators of Nuclear LaminsR01CA211866 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIAO, XIANGSHU · 2017 to 2022
$2.2M
Targeting Hsp60 to Inhibit CREB-mediated Gene TranscriptionR01GM122820 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIAO, XIANGSHU · 2017 to 2023
$1.9M
Chemical tools to decode nuclear lamina-omeR21EB028425 · NIBIB · OREGON HEALTH & SCIENCE UNIVERSITY · PI LI, BINGBING · 2020 to 2022
$616k
NCI NIH HHS R01 CA211866NCI NIH HHS R01 CA278058NIBIB NIH HHS R21 EB028425NIGMS NIH HHS R01 GM122820
6 · The paper itself

Abstract

Protein synthesis and subsequent delivery to the target locations in cells are essential for their proper functions. Methods to label and distinguish newly synthesized proteins from existing ones are critical to assess their differential properties, but such methods are lacking. We describe the first chemical genetics-based approach for selective labeling of existing and newly synthesized proteins that we termed as

Identifiers

PMID37961390
PMCPMC10635081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.